The methylation rate of RASSF1A is 27.4% (174/634 cases) in patients without contralateral UTUC recurrence, and only 6.7% (2/30 cases) in patients with contralateral UTUC recurrence. Here, RASSF1 is linked to renal pelvis/ureter urothelial carcinoma.